GSK: shows progress in oncology portfolio at ESMO
(CercleFinance.com) - GlaxoSmithKline will present new data at the upcoming 2020 Virtual Congress of the European Society of Medical Oncology (ESMO).
The company aims to advance its strong-growth oncology portfolio, which includes recent European Commission (EC) and US Food and Drug Administration (FDA) approvals of BLENREP (belantamab mafodotin) for patients with relapsed/refractory multiple myeloma, and the FDA's approval of a new indication in first-line ovarian cancer for ZEJULA (niraparib).
Dr Axel Hoos, Senior Vice President and Head of Oncology R&D, GSK said, "This year we have achieved strong momentum for our oncology pipeline, with 14 assets in clinical development across four key research areas".
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The company aims to advance its strong-growth oncology portfolio, which includes recent European Commission (EC) and US Food and Drug Administration (FDA) approvals of BLENREP (belantamab mafodotin) for patients with relapsed/refractory multiple myeloma, and the FDA's approval of a new indication in first-line ovarian cancer for ZEJULA (niraparib).
Dr Axel Hoos, Senior Vice President and Head of Oncology R&D, GSK said, "This year we have achieved strong momentum for our oncology pipeline, with 14 assets in clinical development across four key research areas".
Copyright (c) 2020 CercleFinance.com. All rights reserved.